Literature DB >> 25381984

Hyperuricemia in patients with chronic plaque psoriasis.

Paolo Gisondi1.   

Abstract

Psoriasis is frequently associated with obesity, which may favor the development of hyperuricemia. Hyperuricemia predisposes patients to gout arthritis and is an emerging cardiovascular risk factor. In this study, we investigated the prevalence of hyperuricemia and serum uric acid (SUA) levels in psoriatic patients. SUA was measured in consecutive psoriatic patients (n = 338) and prevalence of hyperuricemia was estimated. Hyperuricemia was defined as SUA ≥7 mg/dL in men and ≥6 mg/dL in women. Hyperuricemia affected 20% (67 out 338) of patients with psoriasis. SUA levels were 5.8 ± 1.6 (mean ± SD) in patients with psoriasis. Levels of SUA were significantly higher in obese patients compared to non-obese patients (6.1 ± 1.5 vs 5.2 ± 1.4, P < 0.05). Levels of SUA showed a significant, positive correlation with body mass index (r = 0.30; P < 0.01) and serum triglycerides (r = 0.31; P < 0.01) but they were not significantly associated with age, sex, psoriasis duration or Psoriasis Area Severity Index score. Hyperuricemia is a common finding in psoriatic patients. Dosing levels of SUA could be appropriate in the global management of patients with psoriasis, particularly in those who are obese and with serum triglycerides upper the normal range.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  body mass index; cardiovascular risk; hyperuricemia; psoriasis; serum uric acid

Mesh:

Substances:

Year:  2014        PMID: 25381984     DOI: 10.1002/ddr.21201

Source DB:  PubMed          Journal:  Drug Dev Res        ISSN: 0272-4391            Impact factor:   4.360


  3 in total

1.  The effect of subcutaneous methotrexate on markers of metabolic syndrome in psoriatic patients - preliminary report.

Authors:  Agnieszka Owczarczyk-Saczonek; Marek Drozdowski; Agata Maciejewska-Radomska; Dariusz Choszcz; Waldemar Placek
Journal:  Postepy Dermatol Alergol       Date:  2018-02-20       Impact factor: 1.837

Review 2.  Prevention and risk assessment of cardiovascular events in a population of patients with psoriasis and psoriatic arthritis.

Authors:  Robert Olszewski; Klaudia Ćwiklińska; Maria Maślińska; Brygida Kwiatkowska
Journal:  Reumatologia       Date:  2022-09-07

Review 3.  Plasma total antioxidant capacity and peroxidation biomarkers in psoriasis.

Authors:  Ilaria Peluso; Arturo Cavaliere; Maura Palmery
Journal:  J Biomed Sci       Date:  2016-07-04       Impact factor: 8.410

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.